FDG-PET Patterns Predict Amyloid Deposition and Clinical Profile in Corticobasal Syndrome

Imagem de Miniatura
Arquivos
art_PARMERA_FDGPET_Patterns_Predict_Amyloid_Deposition_and_Clinical_Profile_2021.PDF (3.58 MB)
Citações na Scopus
22
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
Citação
MOVEMENT DISORDERS, v.36, n.3, p.651-661, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Corticobasal syndrome (CBS) is an atypical parkinsonian syndrome related to multiple underlying pathologies. Objective To investigate if individual brain [F-18]fluorodeoxyglucose-positron emission tomography (FDG-PET) patterns could distinguish CBS due to Alzheimer's disease (AD) from other pathologies based on [C-11]Pittsburgh Compound-B (PIB)-PET. Methods Forty-five patients with probable CBS were prospectively evaluated regarding cognitive and movement disorders profile. They underwent FDG-PET and were distributed into groups: likely related to AD (CBS FDG-AD) or likely non-AD (CBS FDG-nonAD) pathology. Thirty patients underwent PIB-PET on a hybrid PET-magnetic resonance imaging equipment to assess their amyloid status. FDG and PIB-PET images were classified individually based on visual and semi-quantitative analysis, blinded to each other. Quantitative group analyses were also performed. Results CBS FDG-AD group demonstrated worse cognitive performances, mostly concerning attention, memory, visuospatial domains, and displayed more myoclonus and hallucinations. The non-AD metabolic group presented more often limb dystonia, ocular motor dysfunction, motor perseveration, and dysarthria. All patients classified as CBS FDG-AD tested positive at PIB-PET compared to 3 of 20 in the non-AD group. The individual FDG-PET classification demonstrated 76.92% of sensitivity, 100% of specificity and positive predictive value and 88.5% of balanced accuracy to detect positive PIB-PET scans. Individuals with positive and negative PIB-PET showed hypometabolism in posterior temporoparietal areas and in thalamus and brainstem, respectively, mainly contralateral to most affected side, disclosing possible metabolic signatures of CBS variants. Conclusion FDG-PET was useful to predict AD and non-AD CBS variants depicting their specific degeneration patterns, different clinical features, and brain amyloid deposition. (c) 2020 International Parkinson and Movement Disorder Society
Palavras-chave
corticobasal syndrome, corticobasal degeneration, positron emission tomography, [F-18]fluorodeoxyglucose, amyloid PET
URI
https://observatorio.fm.usp.br/handle/OPI/40734
Referências
  1. Armstrong MJ, 2013, NEUROLOGY, V80, P496, DOI 10.1212/WNL.0b013e31827f0fd1
  2. Benvenutto A, 2020, J ALZHEIMERS DIS, V74, P331, DOI 10.3233/JAD-190961
  3. Boeve BF, 2003, ANN NEUROL, V54, pS15, DOI 10.1002/ana.10570
  4. Boxer AL, 2019, LANCET NEUROL, V18, P549, DOI 10.1016/S1474-4422(19)30139-5
  5. Boyd CD, 2014, NEUROLOGY, V83, P510, DOI 10.1212/WNL.0000000000000667
  6. Brucki SMD, 2003, ARQ NEURO-PSIQUIAT, V61, P777, DOI 10.1590/S0004-282X2003000500014
  7. Burrell JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061025
  8. Cassidy Adam, 2016, Pract Neurol, V16, P317, DOI 10.1136/practneurol-2015-001354
  9. Cerami C, 2020, J ALZHEIMERS DIS, V76, P517, DOI 10.3233/JAD-200153
  10. Cesar KG, 2017, INT PSYCHOGERIATR, V29, P1345, DOI 10.1017/S1041610217000734
  11. Chand P, 2006, MOVEMENT DISORD, V21, P2018, DOI 10.1002/mds.21055
  12. Coutinho AM, 2020, EUR J NUCL MED MOL I, V47, P2666, DOI 10.1007/s00259-020-04714-0
  13. Cummings JL, 1997, NEUROLOGY, V48, pS10, DOI 10.1212/WNL.48.5_Suppl_6.10S
  14. Della Rosa PA, 2014, NEUROINFORMATICS, V12, P575, DOI 10.1007/s12021-014-9235-4
  15. Di Stefano F, 2016, ALZHEIMERS DEMENT, V12, P786, DOI 10.1016/j.jalz.2016.02.005
  16. Drzezga A, 2003, EUR J NUCL MED MOL I, V30, P1104, DOI 10.1007/s00259-003-1194-1
  17. Eckert T, 2005, NEUROIMAGE, V26, P912, DOI 10.1016/j.neuroimage.2005.03.012
  18. FAZEKAS F, 1989, J NUCL MED, V30, P1607
  19. Goetz CG, 2004, MOVEMENT DISORD, V19, P1020, DOI 10.1002/mds.20213
  20. Hellwig S, 2012, NEUROLOGY, V79, P1314, DOI 10.1212/WNL.0b013e31826c1b0a
  21. Hoglinger GU, 2017, MOVEMENT DISORD, V32, P853, DOI 10.1002/mds.26987
  22. Hu WT, 2009, MOVEMENT DISORD, V24, P1375, DOI 10.1002/mds.22574
  23. HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566
  24. Imamura A, 2009, MOVEMENT DISORD, V24, P152, DOI 10.1002/mds.21877
  25. Jabbari E, 2020, JAMA NEUROL, V77, P377, DOI 10.1001/jamaneurol.2019.4347
  26. Jack CR, 2018, ALZHEIMERS DEMENT, V14, P535, DOI 10.1016/j.jalz.2018.02.018
  27. Kasanuki K, 2018, NEUROLOGY, V91, pE268, DOI 10.1212/WNL.0000000000005828
  28. Lee SE, 2011, ANN NEUROL, V70, P327, DOI 10.1002/ana.22424
  29. Ling HL, 2010, BRAIN, V133, P2045, DOI 10.1093/brain/awq123
  30. Mathew R, 2011, DEMENT GERIATR COGN, V31, P254, DOI 10.1159/000327169
  31. Meyer PT, 2017, J NUCL MED, V58, P1888, DOI 10.2967/jnumed.116.186403
  32. Minoshima S, 1997, ANN NEUROL, V42, P85, DOI 10.1002/ana.410420114
  33. Niccolini F, 2018, EUR J NUCL MED MOL I, V45, P2413, DOI 10.1007/s00259-018-4104-2
  34. Niethammer M, 2014, BRAIN, V137, P3036, DOI 10.1093/brain/awu256
  35. Nobili F, 2018, EUR J NEUROL, V25, P1201, DOI 10.1111/ene.13728
  36. Pardini M, 2019, NEUROLOGY, V92, pE1121, DOI 10.1212/WNL.0000000000007038
  37. PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323
  38. REBEIZ JJ, 1968, ARCH NEUROL-CHICAGO, V18, P20, DOI 10.1001/archneur.1968.00470310034003
  39. Respondek G, 2020, MOVEMENT DISORD, V35, P171, DOI 10.1002/mds.27872
  40. Sakae N, 2019, ALZHEIMERS DEMENT, V15, P1218, DOI 10.1016/j.jalz.2019.04.011
  41. Sha SJ, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-014-0093-y
  42. Shelley BP, 2009, MOVEMENT DISORD, V24, P1593, DOI 10.1002/mds.22558
  43. Smith R, 2017, NEUROLOGY, V89, P845, DOI 10.1212/WNL.0000000000004264
  44. Sperling RA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007941
  45. Tartaglia MC, 2010, ACTA NEUROPATHOL, V119, P365, DOI 10.1007/s00401-009-0605-1
  46. Taswelll C, 2015, J NUCL MED, V56, P1547, DOI 10.2967/jnumed.115.161067
  47. Tripathi M, 2013, NEURORADIOLOGY, V55, P483, DOI 10.1007/s00234-012-1132-7
  48. Walker Z, 2018, EUR J NUCL MED MOL I, V45, P1534, DOI 10.1007/s00259-018-4031-2
  49. Yamane T, 2017, EUR J NUCL MED MOL I, V44, P850, DOI 10.1007/s00259-016-3591-2
  50. Yassuda Mônica Sanches, 2017, Dement. neuropsychol., V11, P48, DOI 10.1590/1980-57642016dn11-010008

Coleções
Artigos e Materiais de Revistas Científicas - FM/MNE
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/15
Artigos e Materiais de Revistas Científicas - LIM/34
Carregar mais